GEN Exclusives

More »

GEN News Highlights

More »
Nov 8, 2006

Biovitrum to Improve Manufacturing Process for Protein-based Allergy Candidate

  • Biovitrum will develop and manufature Resistentia Pharmaceuticals’ new protein-based allergy drug, RES 08, for use in Phase III trials, under an agreement between the companies.

    Biovitrum will expand on the existing process for the biotechnical manufacturing of RES 08 to a standard that meets the high demands of a Phase III trial and manufacture sufficient amounts of the drug for the trial. The project will run for more than two years beginning in November.



Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Should “Special K” Get Special Treatment?

In the near term, what is the best way to use ketamine in treating depression?